85 related articles for article (PubMed ID: 38609704)
1. Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data.
Uemura K; Ito H; Jikuya R; Kondo T; Tatenuma T; Kawahara T; Ito Y; Komeya M; Muraoka K; Hasumi H; Uemura H; Makiyama K
Int J Urol; 2024 Jun; 31(6):678-684. PubMed ID: 38402449
[TBL] [Abstract][Full Text] [Related]
2. Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.
Uchimoto T; Tsuchida S; Komura K; Fukuokaya W; Adachi T; Hirasawa Y; Hashimoto T; Yoshizawa A; Saruta M; Hashimoto M; Higashio T; Matsuda T; Nishimura K; Tsujino T; Nakamura K; Fukushima T; Nishio K; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Takahara K; Inamoto T; Miki J; Fujita K; Kimura T; Ohno Y; Shiroki R; Uemura H; Azuma H
Target Oncol; 2024 May; 19(3):401-410. PubMed ID: 38546942
[TBL] [Abstract][Full Text] [Related]
3. Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy.
Rosenberg JE; Mamtani R; Sonpavde GP; Loriot Y; Duran I; Lee JL; Matsubara N; Vulsteke C; Castellano D; Sridhar SS; Pappot H; Gurney H; Bedke J; van der Heijden MS; Galli L; Keam B; Masumori N; Meran J; O'Donnell PH; Park SH; Grande E; Sengeløv L; Uemura H; Skaltsa K; Campbell M; Matsangou M; Wu C; Hepp Z; McKay C; Powles T; Petrylak DP
Eur Urol; 2024 Jun; 85(6):574-585. PubMed ID: 38418343
[TBL] [Abstract][Full Text] [Related]
4. C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.
Uchimoto T; Matsuda T; Komura K; Fukuokaya W; Adachi T; Hirasawa Y; Hashimoto T; Yoshizawa A; Saruta M; Hashimoto M; Higashio T; Tsuchida S; Nishimura K; Tsujino T; Nakamura K; Fukushima T; Nishio K; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Takahara K; Inamoto T; Miki J; Fujita K; Kimura T; Ohno Y; Shiroki R; Uemura H; Azuma H
Target Oncol; 2024 May; ():. PubMed ID: 38807017
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study.
Minato A; Furubayashi N; Nagata Y; Tomoda T; Masaoka H; Song Y; Hori Y; Kiyoshima K; Negishi T; Kuroiwa K; Seki N; Tomisaki I; Harada K; Nakamura M; Fujimoto N
Curr Oncol; 2024 Feb; 31(2):862-871. PubMed ID: 38392058
[TBL] [Abstract][Full Text] [Related]
6. Real-World Insights into Efficacy and Safety of Enfortumab Vedotin in Japanese Patients with Metastatic Urothelial Carcinoma: Findings, Considerations, and Future Directions.
Endo Y; Akatsuka J; Takeda H; Hasegawa H; Yanagi M; Toyama Y; Mikami H; Shibasaki M; Kimura G; Kondo Y
Curr Oncol; 2024 Jan; 31(2):759-768. PubMed ID: 38392050
[TBL] [Abstract][Full Text] [Related]
7. Translational PET Imaging of Nectin-4 Expression in Multiple Different Cancers with
Zhang J; Duan X; Chen X; Zhang Z; Sun H; Shou J; Zhao G; Wang J; Ma Y; Yang Y; Tian X; Shen Q; Yu W; He Z; Fan Y; Yang X
J Nucl Med; 2024 May; 65(Suppl 1):12S-18S. PubMed ID: 38719240
[TBL] [Abstract][Full Text] [Related]
8. Enfortumab Vedotin Drug Eruption: Cutaneous Adverse Events and Histopathologic Findings.
Casale F; Roth G; Wanat K; Saab-Chalhoub M
Am J Dermatopathol; 2024 Jun; ():. PubMed ID: 38842397
[TBL] [Abstract][Full Text] [Related]
9. Racial Differences in Cutaneous Events Among Patients Receiving Enfortumab Vedotin.
Vlachou E; Mamtani R; Hahn NM; Iii BJ; Hoffman-Censits J; Nimgaonkar V
Clin Genitourin Cancer; 2024 Jun; 22(3):102090. PubMed ID: 38688798
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: A retrospective multicenter study in Japan.
Hara T; Matsushita Y; Harada K; Fujimoto N; Fujisawa M; Miyake H
Int J Urol; 2024 Jun; 31(6):696-698. PubMed ID: 38424707
[No Abstract] [Full Text] [Related]
11. Therapies After Progression on Enfortumab Vedotin and Pembrolizumab: Navigating Second-line Options for Metastatic Urothelial Carcinoma in the New Treatment Landscape.
Brown JR; Koshkin VS
Eur Urol Focus; 2024 May; ():. PubMed ID: 38797658
[TBL] [Abstract][Full Text] [Related]
12. Editorial: Innovative molecular therapeutic approaches in urothelial carcinoma.
Holder SL; Yin M; Joshi M
Front Oncol; 2024; 14():1430285. PubMed ID: 38835376
[No Abstract] [Full Text] [Related]
13. Is HER2 the New NECTIN4 in Advanced Urothelial Cancer?
Nally E; Young M; Wells C; Fairhead R; Baines K; Cheney-Lowe H; Jackson-Spence F; Powles T
Eur Urol Focus; 2024 Jun; ():. PubMed ID: 38825408
[TBL] [Abstract][Full Text] [Related]
14. SDRIFE and bullous reaction after treatment with enfortumab vedotin plus pembrolizumab: Case series.
Lluch-Galcerá JJ; Manzanares-Oliver N; Martinez-Molina M; Valdivieso L; Boada A; Segura S; Rovira R; Pujol RM; Jaka A
J Dtsch Dermatol Ges; 2024 May; ():. PubMed ID: 38778438
[No Abstract] [Full Text] [Related]
15. Antibody drug conjugate combats inflammation.
Crunkhorn S
Nat Rev Drug Discov; 2024 May; 23(5):340. PubMed ID: 38575784
[No Abstract] [Full Text] [Related]
16. Toxicities of Novel Agents for the Treatment of Advanced Bladder Cancer.
McInerney S; Jones RJ
Eur Urol Focus; 2024 Jun; ():. PubMed ID: 38851928
[TBL] [Abstract][Full Text] [Related]
17. Clinical Pharmacology of the Antibody-Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors.
Tang M; Garg A; Bonate PL; Rosenberg JE; Matsangou M; Kadokura T; Yamada A; Choules M; Pavese J; Nagata M; Tenmizu D; Koibuchi A; Heo N; Wang L; Wojtkowski T; Hanley WD; Poondru S
Clin Pharmacokinet; 2024 Apr; 63(4):423-438. PubMed ID: 38609704
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma.
Takahashi S; Uemura M; Kimura T; Kawasaki Y; Takamoto A; Yamaguchi A; Melhem-Bertrandt A; Gartner EM; Inoue T; Akazawa R; Kadokura T; Tanikawa T
Invest New Drugs; 2020 Aug; 38(4):1056-1066. PubMed ID: 31444589
[TBL] [Abstract][Full Text] [Related]
19. Enfortumab vedotin to treat urothelial carcinoma.
Hanna KS
Drugs Today (Barc); 2020 May; 56(5):329-335. PubMed ID: 32406880
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
